Biotech has a romantic story it likes to tell about discovery. A lone scientist sees what no one else sees. The data line up. The breakthrough arrives.

In practice, the work looks more like a long series of meetings where smart people disagree about what the data mean, what the next experiment should be, and what risks are worth taking. When those rooms are filled with people who think alike, the disagreement turns shallow. You get speed, but you do not always get truth.

Leen Kawas has built her career inside those rooms, first as a scientist and founder, then as an operator and investor. She is CEO of EIT Pharma, serves on the board of Inherent Biosciences, and is a co-founder and managing general partner of Propel Bio Partners, a life science venture fund. Earlier, she co-founded Athira Pharma, led it through late-stage clinical development, and took the company public in 2020. 

Across profiles and interviews, Kawas has returned to a consistent idea: diversity is not a social accessory to innovation. It is part of the mechanism. 

Diversity works like a better experimental design

In medicine, a study can fail because it asks the wrong question. It can fail because it selects the wrong population. It can fail because it never tests its assumptions against reality.

Teams can fail the same way.

Kawas has described being motivated by the exchange of ideas that comes from building teams with varied backgrounds, linking that diversity directly to innovation rather than to optics. The core logic is familiar to anyone who has run experiments: you want enough variation in your inputs to notice what is actually driving your output.

A team that includes different training paths and life experiences is more likely to challenge a cherished theory, spot a missing control, or ask why a plan assumes unlimited time and money. That friction can feel slower in the moment. It can prevent months of work spent pursuing the wrong signal.

The patient population is diverse, even when the pipeline is not

Biotech innovation is supposed to end at a patient. Patients do not come in one default model. They come with different genetics, different comorbidities, different constraints around access, caregiving, work, language, and trust.

When a leadership team lacks perspective, it can design development programs that are technically rigorous and practically fragile. Recruitment plans that ignore transportation barriers. Protocols that overload clinic visits. Endpoints that make sense to scientists and land poorly in real life.

Kawas’ work spans drug development and investment. Inherent Biosciences describes her board contributions in terms of drug discovery, clinical trial methodology, regulatory strategy, commercialization, and financing. Those domains are not just technical lanes. They are points where human experience collides with strategy. A team that includes people who have navigated those collisions in different ways tends to build sturdier plans.

Founding forces you to see how much you do not know

Leen Kawas came to the United States from Jordan in 2008, then built a track that moved from scientific work into company building. If you want to understand why she emphasizes diversity, look at what it takes to bring a biotech company to the public markets.

Athira’s IPO in 2020 raised $204 million, according to contemporaneous reporting. Propel Bio Partners’ biography notes that the public-market milestone came in the context of raising over $400 million around that period. 

That scale of execution requires collaboration across scientific, clinical, regulatory, operational, and financial disciplines. It also requires a founder to accept that intelligence is not enough. What matters is the ability to integrate different kinds of expertise into one coherent plan.

Kawas’ later move into launching Propel Bio Partners is telling. The fund positions her as someone leveraging her experience as an inventor, scientist, and entrepreneur to back life science innovation. Investing is pattern recognition. If your pattern library is narrow, you miss good founders who do not match the industry’s default template. You also miss good ideas that come from unconventional paths.

Diversity is a risk management strategy

There is a version of diversity talk that is aspirational and vague. Kawas’ framing tends to be more operational.

A diverse team is harder to manage in one specific way: it will not let leadership glide on untested assumptions. That is a feature. In high-stakes science, unchecked assumptions are expensive.

In her interview with the French-American Foundation, Kawas emphasized building a team with diverse backgrounds and linked that diversity to the energy of idea-sharing and innovation. Read as management philosophy, it is an argument about error prevention. When the room is varied, weak ideas get stress-tested earlier. Blind spots get named sooner. The plan gets revised while revision is still affordable.

Innovation needs translation, and translation needs representation

Leen Kawas’ roles today sit on the bridge between invention and execution. EIT Pharma presents her as CEO. Inherent Biosciences highlights her experience across the chain from discovery to financing. Propel Bio Partners highlights her focus on building a biotech-focused fund to support life science innovations. 

Those positions involve constant translation. Translating science into a development plan. Translating a development plan into a fundraising story that stays honest. Translating a company’s goals into hiring decisions and culture.

Diversity fuels innovation here because translation improves when the translator understands the audience. A team that includes more lived contexts can anticipate how a product, a trial design, or a business model will land outside the founding circle.

What leaders can take from Kawas’ view

Kawas’ story suggests a practical conclusion: if you want innovation, treat diversity as infrastructure.

Build teams where difference is real, not cosmetic. Then make the culture strong enough to hold disagreement without turning it into politics. The aim is not harmony. The aim is better decisions.

In biotech, the costs of being wrong are measured in time and in patients waiting. Kawas’ insistence that diversity drives innovation reads less like a slogan and more like a commitment to building rooms where the truth has a better chance of surviving. 

Learn more about Leen Kawas in her interview with Principal Post.